Osteolytic Lesions Of Multiple Myeloma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for osteolytic lesions of multiple myeloma. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
3
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Osteolytic Lesions Of Multiple Myeloma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Novartis 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating osteolytic lesions of multiple myeloma. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zometa
ZOLEDRONIC ACID
 Novartis 3 65 — 2028-02-05

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7932241 Zometa other 75 2028-08-05
7932241 Zometa formulation 60 2028-02-05
7932241 Zometa formulation 60 2028-02-05

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7932241 Zometa formulation 60 2028-02-05
7932241 Zometa formulation 60 2028-02-05
7932241 Zometa other 75 2028-08-05

Related